Malignant Pleural Effusion - Pipeline Review, H1 2020

March 2020 | 49 pages | ID: M1CFA58288EEN
Global Markets Direct

Abstracts

Malignant Pleural Effusion - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Pleural Effusion - Pipeline Review, H1 2020, provides an overview of the Malignant Pleural Effusion (Respiratory) pipeline landscape.

Malignant pleural effusion is a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue (pleura) lining the outside of the lung and the wall of the chest cavity. Lung cancer, breast cancer, lymphoma, and leukemia cause most malignant pleural effusions.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Pleural Effusion - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Malignant Pleural Effusion (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Pleural Effusion (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Effusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 4 and 2 respectively.

Malignant Pleural Effusion (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Pleural Effusion (Respiratory).
• The pipeline guide reviews pipeline therapeutics for Malignant Pleural Effusion (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Malignant Pleural Effusion (Respiratory) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Malignant Pleural Effusion (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Pleural Effusion (Respiratory)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Malignant Pleural Effusion (Respiratory).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Malignant Pleural Effusion (Respiratory) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Malignant Pleural Effusion - Overview
Malignant Pleural Effusion - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Malignant Pleural Effusion - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Malignant Pleural Effusion - Companies Involved in Therapeutics Development
Amgen Inc
Biogen Inc
BioSyngen Pte Ltd
Clover Biopharmaceuticals
Genelux Corp
Gongwin Biopharm Holdings Co Ltd
Hubei Soundny Bio-Tech Co Ltd
Lipac Oncology LLC
Malignant Pleural Effusion - Drug Profiles
BG-00001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BSG-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
methotrexate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olvimulogene nanivacirepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
paclitaxel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTS-500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCB-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
talimogene laherparepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Malignant Pleural Effusion - Dormant Projects
Malignant Pleural Effusion - Product Development Milestones
Featured News & Press Releases
Jan 10, 2020: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Pleural Effusions (MPE)
Nov 21, 2019: Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)
Sep 29, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Ascites
May 12, 2015: Genelux to Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 at ASCO Annual Meeting 2015
Jun 15, 2013: Genelux Presents Abstracts at the 7th International Meeting on Replicating Oncolytic Virus Therapeutics in Quebec
May 30, 2013: Genelux To Present Abstracts For Clinical Trials Of Oncolytic Viral Therapy GL-ONC1 At 2013 ASCO Annual Meeting
Feb 06, 2013: Genelux Announces Treatment Of First Patient In Phase I Trial With GL-ONC1 At Memorial Sloan Kettering Cancer Center
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Malignant Pleural Effusion, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Malignant Pleural Effusion - Pipeline by Amgen Inc, H1 2020
Malignant Pleural Effusion - Pipeline by Biogen Inc, H1 2020
Malignant Pleural Effusion - Pipeline by BioSyngen Pte Ltd, H1 2020
Malignant Pleural Effusion - Pipeline by Clover Biopharmaceuticals, H1 2020
Malignant Pleural Effusion - Pipeline by Genelux Corp, H1 2020
Malignant Pleural Effusion - Pipeline by Gongwin Biopharm Holdings Co Ltd, H1 2020
Malignant Pleural Effusion - Pipeline by Hubei Soundny Bio-Tech Co Ltd, H1 2020
Malignant Pleural Effusion - Pipeline by Lipac Oncology LLC, H1 2020
Malignant Pleural Effusion - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Malignant Pleural Effusion, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Amgen Inc
Biogen Inc
BioSyngen Pte Ltd
Clover Biopharmaceuticals
Genelux Corp
Gongwin Biopharm Holdings Co Ltd
Hubei Soundny Bio-Tech Co Ltd
Lipac Oncology LLC